Moreover, pharmacological inhibition of AChR or Src by treatment with methyllycaconitine (MLA) or dasatinib, respectively, significantly suppressed the NNK-induced tumor multiplicity and load in mice (Fig. 3l), along with decreases in the expression of pSrc and AGT (Fig. 3m). The gene discussed is SRC; the disease is neoplasm.